Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Vivani Medical entered into agreement with Novo Nordisk to evaluate its miniature subdermal semaglutide (GLP-1) implant for weight management
Vivani Medical entered into agreement with Novo Nordisk to evaluate its miniature subdermal semaglutide (GLP-1) implant for weight management
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.